Your bioinformatics partner
enGenome is passionate about developing cutting-edge solutions to light the way in your genomic journey.
Enhance healthcare with advanced genomics
eVai platform enables precise and early diagnosis of Rare Disease ensuring unprecedented accuracy in interpreting genomic variants.
Excellence in monogenic interpretation
Winner of the NIH-funded CAGI6 Challenge, eVai platform automates ACMG guidelines and prioritizes variants to highlight candidate diagnoses.
Here’s why clients choose enGenome
→ Pathogenic variants ranked in first positions
→ Classification accuracy up to 98%
→ VUS reduction up to 60%
→ Intuitive and Fast
→ Secure, CE-IVD and ISO 13485 certified
Automated ACMG Classification
eVai automatically pre-classifies SNV, Indels and CNVs according to international guidelines. The classification is disease-specific and reports both the activated criteria and the supporting evidence.
Automated ACMG Classification
eVai automatically pre-classifies SNV, Indels and CNVs according to international guidelines. The classification is disease-specific and reports both the activated criteria and the supporting evidence.
AI-powered Prioritization
eVai leverages our proprietary AI technology to assign a pathogenicity score to each variant, enabling their prioritization for hypothesis-free or hypothesis-driven approach. Even VUS get a score and can be stratified.
Variant Filtering
eVai enables users to create virtual gene panels and custom variant filters by leveraging on multiple omics resources such as Human Phenotype Ontology.
eVai guarantees the highest level of security, privacy and quality and is CE IVD-certified
Contact – Responsible Manager
Tomáš Straka
Business Development Manager – Diagnostics, IVF
E-mail: straka@3genes.com
Mobile: +420733202307